​

Marker Therapeutics (MRKR) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

Marker Therapeutics Revenue Highlights

Latest Revenue (Y)

$3.55T

Latest Revenue (Q)

$861.18K

Main Segment (Y)

Grant

Marker Therapeutics Revenue by Period

Marker Therapeutics Revenue by Year

DateRevenueChange
2025-12-31$3.55T53810034.30%
2024-12-31$6.59M99.06%
2023-12-31$3.31M-5.76%
2022-12-31$3.51M182.96%
2021-12-31$1.24M166.01%
2020-12-31$466.79K118.95%
2019-12-31$213.19K3.50%
2018-12-31$205.99K12.53%
2017-12-31$183.06K100.00%
2016-12-31-100.00%
2015-12-31-100.00%
2014-12-31-100.00%
2013-12-31-100.00%
2012-12-31-100.00%
2011-12-31-100.00%
2010-12-31-100.00%
2009-12-31-100.00%
2008-12-31-100.00%
2007-12-31-100.00%
2006-12-31-100.00%
2005-12-31-100.00%
2004-12-31-100.00%
2003-12-31-100.00%
2002-12-31-100.00%
2001-12-31--100.00%
2000-12-31$31.81K-73.65%
1999-12-31$120.72K-

Marker Therapeutics generated $3.55T in revenue during NA 2025, up 53810034.30% compared to the previous quarter, and up 759807834.44% compared to the same period a year ago.

Marker Therapeutics Revenue by Quarter

DateRevenueChange
2025-06-30$861.18K146.68%
2025-03-31$349.10K-84.50%
2024-12-31$2.25M16.93%
2024-09-30$1.93M64.76%
2024-06-30$1.17M-6.03%
2024-03-31$1.24M17.69%
2023-12-31$1.06M310.32%
2023-09-30$257.61K-66.22%
2023-06-30$762.66K-78.21%
2023-03-31$3.50M-42.20%
2022-12-31$6.05M53.29%
2022-09-30$3.95M399.37%
2022-06-30$791.00K-17.95%
2022-03-31$964.00K-22.38%
2021-12-31$1.24M100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31--100.00%
2020-12-31$215.00100.00%
2020-09-30--100.00%
2020-06-30$466.79K100.00%
2020-03-31--100.00%
2019-12-31$213.19K100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31--100.00%
2018-12-31$6.00100.00%
2018-09-30--100.00%
2018-06-30$205.99K100.00%
2018-03-31-100.00%
2017-12-31--100.00%
2017-09-30$183.06K100.00%
2017-06-30-100.00%
2017-03-31-100.00%
2016-12-31-100.00%
2016-09-30-100.00%
2016-06-30-100.00%
2016-03-31-100.00%
2015-12-31-100.00%
2015-10-30-100.00%
2015-06-30-100.00%
2015-03-31-100.00%
2014-12-31-100.00%
2014-09-30-100.00%
2014-06-30-100.00%
2014-03-31-100.00%
2013-12-31-100.00%
2013-09-30-100.00%
2013-06-30-100.00%
2013-03-31-100.00%
2012-12-31-100.00%
2012-09-30-100.00%
2012-06-30-100.00%
2012-03-31-100.00%
2011-12-31-100.00%
2011-09-30-100.00%
2011-06-30-100.00%
2011-03-31-100.00%
2010-12-31-100.00%
2010-09-30-100.00%
2010-06-30-100.00%
2010-03-31-100.00%
2009-12-31-100.00%
2009-09-30-100.00%
2009-06-30-100.00%
2009-03-31-100.00%
2008-12-31-100.00%
2008-09-30-100.00%
2008-06-30-100.00%
2008-03-31-100.00%
2007-12-31--

Marker Therapeutics generated $861.18K in revenue during Q2 2025, up 146.68% compared to the previous quarter, and up 69.23% compared to the same period a year ago.

Marker Therapeutics Revenue Breakdown

Marker Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 25Dec 24Dec 23Dec 22Dec 21
Grant$3.55M$6.59M$3.51M--
Related Party Service--$3.50M--
Service--$816.64K$5.50M-
Grant income----$1.24M

Marker Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 25: Grant (100.00%).

Quarterly Revenue by Product

Product/ServiceDec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 19
Grant$1.10M$1.23M$861.18K$349.10K$2.25M$1.93M$1.17M$1.24M$1.23M$759.14K$999.57K$213.19K---
Service---------$3.50M$2.55M----
Grant income------------$790.51K$964.32K-

Marker Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Grant (100.00%).

Marker Therapeutics Revenue Breakdown by Country

Quarterly Revenue by Country

CountryMar 23Dec 22Sep 22Jun 22Mar 22Dec 19
Grant$1.23M$759.14K$999.57K$213.19K--
Service$3.50M$2.55M----
Grant income---$790.51K$964.32K-

Marker Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 23: Service (73.93%), and Grant (26.07%).

Marker Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
MRKRMarker Therapeutics$3.55T$861.18K
BOLTBolt Biotherapeutics$7.70M$2.17M
EVGNEvogene$5.64M$4.19M
IMNNImunon--
GLTOGalecto--
COCPCocrystal Pharma--
PHIOPhio Pharmaceuticals--
CLRBCellectar Biosciences--
SNSESensei Biotherapeutics--
MBIOMustang Bio--

MRKR Revenue FAQ

What is Marker Therapeutics’s yearly revenue?

Marker Therapeutics's yearly revenue for 2025 was $3.55T, representing an increase of 53810034.30% compared to 2024. The company's yearly revenue for 2024 was $6.59M, representing an increase of 99.06% compared to 2023. MRKR's yearly revenue for 2023 was $3.31M, representing a decrease of -5.76% compared to 2022.

What is Marker Therapeutics’s quarterly revenue?

Marker Therapeutics's quarterly revenue for Q2 2025 was $861.18K, a 146.68% increase from the previous quarter (Q1 2025), and a -26.33% decrease year-over-year (Q2 2024). The company's quarterly revenue for Q1 2025 was $349.1K, a -84.50% decrease from the previous quarter (Q4 2024), and a -71.94% decrease year-over-year (Q1 2024). MRKR's quarterly revenue for Q4 2024 was $2.25M, a 16.93% increase from the previous quarter (Q3 2024), and a 113.06% increase year-over-year (Q4 2023).

What is Marker Therapeutics’s revenue growth rate?

Marker Therapeutics's revenue growth rate for the last 3 years (2023-2025) was 107113356.33%, and for the last 5 years (2021-2025) was 285627703.59%.

What are Marker Therapeutics’s revenue streams?

Marker Therapeutics's revenue streams in c 25 are Grant

What is Marker Therapeutics’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Marker Therapeutics was Grant. This segment made a revenue of $3.55M, representing 100.00% of the company's total revenue.